Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common type of vascular malformation, with skin involvement impacting an estimated approximately 50-80% of patients, which can result in bleeding, thrombosis, ulceration, disfigurement, and proliferation QTORIN™ rapamycin has the potential to be the first approved therapy in the U.S. for more than an estimated 75,000 ...

交易与所有权结构 - Pasinex土耳其子公司签署补充协议 推进对Sarıkaya锌项目100%所有权的收购 [1][2] - 股份转让需获得土耳其矿产石油事务总局批准 完成后将完全持有Aydın Teknik公司和Sarıkaya许可证 [3] - 剩余应付款项为225万美元 其中25万美元将于2025年9月30日前支付以触发股份转让 200万美元通过股权质押方式分期支付至2027年6月30日 [9] 项目开发计划 - 计划2025年第四季度开始巷道延伸工程 目标接触新发现的高品位锌矿带（锌品位约30%-50%） [5] - 2026年第一至第二季度启动采矿作业 由全资子公司Horzum AŞ管理团队实施 [5] - 同步开展系统测绘、采样和地球物理勘察 以确定钻探靶区并完善地质模型 [6] 资源潜力与地质特征 - Sarıkaya为碳酸盐岩型锌矿系统 显示大规模高品位矿化标志 存在长达一公里的未测绘断层带 [7][8] - 矿化受断层控制 局部存在于喀斯特空隙填充中 地表可见铁帽、重晶石及铅锌矿化露头 [8] - 现有巷道内已揭露可直接运输至高品位锌矿体 无需复杂选矿处理 [8] 战略与区位优势 - 项目位于土耳其传统矿业区 距梅尔辛港约300公里 距现有Pinargozu矿山车程约两小时 [7] - 与公司现有Pinargözü矿山形成战略互补 符合在土耳其构建高品位锌矿组合的战略方向 [10] - 通过整合Aydın Teknik和Horzum AŞ的全所有权 强化财务与生产能力 [10] 公司背景与资产组合 - Pasinex为多伦多上市锌矿企业 通过土耳其子公司全资持有Horzum AŞ及其运营的Pinargozu矿山 [11] - 持有内华达州Gunman高品位锌勘探项目51%权益 [12] - 管理团队拥有矿产勘探与矿山开发丰富经验 [12]

融资方案 - 公司宣布进行非经纪私募配售 发行最多10,714,285个单位 每单位价格0.28美元 总收益最高达300万美元 [1][2] - 每个单位包含一股普通股和一份认股权证 认股权证行权价为0.40美元 有效期3年 若公司股价连续20个交易日达到或超过0.65美元 认股权证可能被加速到期 [3] - 融资预计于2025年10月7日左右完成 净收益将用于一般营运资金和勘探开发成本 [6] 发行条款 - 根据上市发行人融资豁免条款向加拿大(魁北克除外)居民发售 该豁免下发行的证券在加拿大不设持有期限制 [4] - 发行相关招股说明书可通过SEDAR+平台和公司网站获取 [5] - 此次发行不构成在美国的要约销售 相关证券未根据1933年证券法注册 [7] 公司背景 - Domestic Metals Corp是一家矿产勘探公司 专注于在美洲历史矿区发现大型铜金矿床 [8] - 公司Smart Creek项目位于蒙大拿州 地表存在广泛铜矿化 包含4个斑岩铜矿、浅成热液金矿等勘探靶区 [9] - 公司由经验丰富的管理团队和技术团队领导 在矿山发现、开发及融资方面拥有成功记录 [9]

Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proport ...

核心交易 - 公司与银团达成协议获得最高2.5亿美元循环信贷额度 并可通过增额条款额外获得1亿美元融资 [1] - 信贷额度由蒙特利尔银行担任行政代理和贷款人 加拿大帝国商业银行和加拿大国民银行担任联合牵头安排人及联合银团代理 [1] - 该融资工具将于2028年9月15日到期 可用于公司一般运营资金及未来投资需求 [2] 融资条款 - 贷款利率采用Term SOFR加年化0.1%信用利差调整 再加2.5%-3.5%适用利差（根据净杠杆率调整） [3] - 美元基准利率贷款采用蒙特利尔银行基准利率加1.5%-2.5%适用利差（根据净杠杆率调整） [3] - 未动用额度需支付0.563%-0.788%年化承诺费（根据净杠杆率调整） [3] 资产与担保 - 融资由公司及其重要子公司全部资产提供担保 [2] - 公司终止与Franco-Nevada GLW Holdings Corp于2025年4月15日签订的1亿美元高级债务协议 该协议终止时未动用 [4] 公司业务概览 - 公司拥有墨西哥奇瓦瓦州100%控股的Cordero项目 为全球最大未开发银矿之一 [5] - 2025年4月15日完成收购Porcupine Complex 成为加拿大黄金生产商 在安大略省Timmins地区拥有主导地位的土地资源 [5]

Series RIKV 26 0318Settlement Date 09/17/2025Total Amount Allocated (MM) 21,018All Bids Awarded At (Price / Simple interest) 96.300/7.600Total Number of Bids Received 25Total Amount of All Bids Received (MM) 31,718Total Number of Successful Bids 18Number of Bids Allocated in Full 18Lowest Price / Highest Simple Interest Allocated 96.300/7.600Highest Price / Lowest Simple Interest Allocated 96.352/<td style="border-right: solid black 1pt ; text-align: right ; vertical-align: m ...

ATH434 demonstrated clinically meaningful efficacy in modifying disease progression and was well tolerated at both 50 and 75 mg dosesMELBOURNE, Australia and SAN FRANCISCO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atro ...

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Plymouth Industrial REIT, Inc. (NYSE: PLYM) (the “Company”) today announced that its board of directors has declared a regular quarterly cash dividend of $0.24 per share of common stock for the third quarter of 2025. The dividend, which equates to an annualized rate of $0.96 per common share, is payable on October 31, 2025, to stockholders of record as of the close of business on September 30, 2025. About PlymouthPlymouth Industrial REIT, Inc. (NYSE: PLYM) is a ful ...

TORONTO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Celestica Inc. (TSX and NYSE: CLS) will hold its third quarter 2025 financial results conference call and 2025 Investor and Analyst Day on Tuesday, October 28, 2025. The conference call start time is 8:00am ET. Financial results will be released after market close on Monday, October 27, 2025. During the conference call, Celestica’s management will provide an update on its business operations, strategic priorities, growth opportunities and its financial outlook. Pa ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that data from its MOON ATS® and OTC Overnight® trading sessions is now available via the ICE Consolidated Feed, Intercontinental Exchange’s (NYSE: ICE) premier normalized data solution. This expansion brings OTC Markets’ trading data into a standardized, low-latency environment widely used by global banks, asset managers, hedg ...